ABOUT US

HISTORY

BCI Pharma was set up (medicinal chemistry lab) in Montpellier (France) in March 2013.
In September 2017 the headquarter moved to Liège (Belgium) and a biology lab was created.
The two founders have extensive expertise in research and patient treatment.

Dr. Dominique Surleraux (CEO) was head of research for a pharmaceutical company (J&J) and two biotech companies (Idenix and Tibotec).
Dr. Elisabeth Picou (Associated director) had a position as physician in a hospital and manages a biology lab.

ABOUT US

OUR STRATEGY

BCI Pharma has a strategic plan that should enable it to have a competitive adventage in the biotech industry, including :

Strategic partnerships, which are the foundation of a successful business
Access to a range of complementary assets
Broad expertise in discovery of new molecules
Fostering innovation

EXECUTIVE TEAM

Dominique Surleraux

Dominique Surleraux

CEO

He received his Ph.D in organic chemistry from the University of Namur (Belgium) and a Master in Drug Design from the University of Lille (France).

More

He began his career as a scientist with Janssen Pharmaceutical (Belgium) working on pain, gastro-intestinal disease, cancer, allergy and virology and left the company as principal scientist after five years.
Then he joined Tibotec (Belgium), working on the Prezista and the TMC435 project (HCV, protease inhibitor). He was director of the medicinal chemistry department; developing anti-infectious research at Johnson & Johnson (Janssen Pharmaceuticals).
Next, he moved to Idenix Pharmaceutical and was Vice-President of the medicinal chemistry department. Under his supervision, the team based in Montpellier delivered promising drugs candidates, HCV nucleotide polymerase inhibitors (IDX21437/21459), HCV non-nucleoside polymerase inhibitor (IDX375), excellent HCV protease inhibitors (IDX320, IDX719) and an NS5A inhibitor (IDX791).

Elisabeth Picou

Elisabeth Picou

ASSOCIATED DIRECTOR

She is a physician and a medical biologist, co-owner of a medical diagnostic laboratory and has a position at the St Eloi Hospital (Montpellier, France), treating patients with infectious diseases.

Sabrina Deroo

Sabrina Deroo

CSO

Sabrina Deroo holds a PhD in Biochemistry from the Katholieke Universiteit Leuven (Belgium) and has more than 18 years expertise in Research and Development in oncology and virology.

More

She started her career as scientist at the Centre de Recherche Public-Santé (now Luxembourg Institute of Health) in the field of virology and left the Institute as Head of the Immuno-Virology Unit after 10 years. She joined Complix Luxembourg S.A. in 2010 as project leader and site manager where she was involved and responsible for internal and collaborative pre-clinical programs based on a novel biotherapeutics platform in the field of oncology. In January 2019 she joined BCI Pharma as CSO.

BOARD OF DIRECTORS

Dominique Surleraux

Elisabeth Picou

Jean-Marc Legrand

Benoît Fellin

Louis de Thanhoffer

SCIENTIFIC ADVISORY BOARD ( SAB)

Georges Skouteris

Mark Martens

Gerhard Muller

Frank Bernhard

ABOUT US

OUR VISION

Our vision is to become :

  • An expert company in kinase research
  • Your preferred partners for your kinase disovery project
  • A biotech company wich which delivers best in class candidates to improve patients treatment or for unmet medical need.

Our aim is to become a world renowned company with high value by our patients, customers, colleagues, investors, business partners and the communities where we work and live.

ABOUT US

OUR VALUES

CUSTOMER FOCUS
We are deeply committed to meeting the needs of our customers and to constantly focusing on customer satisfaction

PERFORMANCE
Providing an environment that promotes creativity and openness to new ideas, leading to the advencement in skills, technology and processes.

COLLABORATION
We know that to be a successful campany we must work together, frequently transcending organizational and geographic boundaries to meet the changing needs of our customers.

INNOVATION
We strive for continuous improvement in our performance, measuring results carefully that integrity and respect for the individual are never compromised.